Race Oncology Limited

ASX:RAC Rapporto sulle azioni

Cap. di mercato: AU$247.2m

Race Oncology Gestione

Gestione criteri di controllo 1/4

Race Oncology Il CEO è Daniel Tillett, nominato in Nov2023, e ha un mandato di meno di un anno. la retribuzione annua totale è A$ 1.12M, composta da 13% di stipendio e 87% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 10.13% delle azioni della società, per un valore di A$ 24.09M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 0.9 anni e 2 anni.

Informazioni chiave

Daniel Tillett

Amministratore delegato

AU$1.1m

Compenso totale

Percentuale dello stipendio del CEO13.0%
Mandato del CEOless than a year
Proprietà del CEO10.1%
Durata media del managementless than a year
Durata media del Consiglio di amministrazione2yrs

Aggiornamenti recenti sulla gestione

Recent updates

Is Race Oncology (ASX:RAC) In A Good Position To Deliver On Growth Plans?

Aug 26
Is Race Oncology (ASX:RAC) In A Good Position To Deliver On Growth Plans?

We Think Race Oncology (ASX:RAC) Needs To Drive Business Growth Carefully

May 10
We Think Race Oncology (ASX:RAC) Needs To Drive Business Growth Carefully

We're Not Very Worried About Race Oncology's (ASX:RAC) Cash Burn Rate

Jan 23
We're Not Very Worried About Race Oncology's (ASX:RAC) Cash Burn Rate

Here's Why We're Not Too Worried About Race Oncology's (ASX:RAC) Cash Burn Situation

Oct 05
Here's Why We're Not Too Worried About Race Oncology's (ASX:RAC) Cash Burn Situation

Companies Like Race Oncology (ASX:RAC) Are In A Position To Invest In Growth

Jun 20
Companies Like Race Oncology (ASX:RAC) Are In A Position To Invest In Growth

We're Interested To See How Race Oncology (ASX:RAC) Uses Its Cash Hoard To Grow

Feb 17
We're Interested To See How Race Oncology (ASX:RAC) Uses Its Cash Hoard To Grow

Here's Why We're Not At All Concerned With Race Oncology's (ASX:RAC) Cash Burn Situation

Oct 14
Here's Why We're Not At All Concerned With Race Oncology's (ASX:RAC) Cash Burn Situation

Here's Why We're Not Too Worried About Race Oncology's (ASX:RAC) Cash Burn Situation

Apr 01
Here's Why We're Not Too Worried About Race Oncology's (ASX:RAC) Cash Burn Situation

We're Hopeful That Race Oncology (ASX:RAC) Will Use Its Cash Wisely

Apr 05
We're Hopeful That Race Oncology (ASX:RAC) Will Use Its Cash Wisely

What Percentage Of Race Oncology Limited (ASX:RAC) Shares Do Insiders Own?

Mar 01
What Percentage Of Race Oncology Limited (ASX:RAC) Shares Do Insiders Own?

How Much Are Race Oncology Limited (ASX:RAC) Insiders Taking Off The Table?

Jan 07
How Much Are Race Oncology Limited (ASX:RAC) Insiders Taking Off The Table?

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Daniel Tillett rispetto agli utili di Race Oncology?
DataCompenso totaleStipendioGuadagni aziendali
Jun 30 2024AU$1mAU$145k

-AU$14m

Mar 31 2024n/an/a

-AU$12m

Dec 31 2023n/an/a

-AU$11m

Sep 30 2023n/an/a

-AU$11m

Jun 30 2023AU$836kAU$332k

-AU$10m

Mar 31 2023n/an/a

-AU$10m

Dec 31 2022n/an/a

-AU$11m

Sep 30 2022n/an/a

-AU$11m

Jun 30 2022AU$1mAU$228k

-AU$11m

Mar 31 2022n/an/a

-AU$10m

Dec 31 2021n/an/a

-AU$9m

Sep 30 2021n/an/a

-AU$8m

Jun 30 2021AU$1mAU$167k

-AU$6m

Mar 31 2021n/an/a

-AU$5m

Dec 31 2020n/an/a

-AU$4m

Sep 30 2020n/an/a

-AU$4m

Jun 30 2020AU$147kn/a

-AU$4m

Compensazione vs Mercato: La retribuzione totale di Daniel ($USD 726.03K ) è circa la media per le aziende di dimensioni simili nel mercato Australian ($USD 696.08K ).

Compensazione vs guadagni: La retribuzione di Daniel è aumentata nonostante l'azienda non sia redditizia.

AMMINISTRATORE DELEGATO

Daniel Tillett

less than a year

Mandato

AU$1,118,157

Compensazione

Dr. Daniel Tillett is Non-Executive Director of Tryptamine Therapeutics Limited from November 8, 2024. Dr. Tillett joined the Tryptamine Therapeutics Limited on November 8, 2024. Dr. Tillett has been Chief...

Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Peter Smith
Executive Chairman1.4yrsAU$327.72kNessun dato
Daniel Tillett
CEO, Managing Director & Directorless than a yearAU$1.12m10.13%
A$ 25.0m
Michelle Rashford
Chief Medical Officer1.3yrsAU$704.81kNessun dato
Brendan Brown
Chief Financial Officerless than a yearNessun datoNessun dato
Sophia Moscovis
Vice President of Operations & Strategyless than a yearNessun datoNessun dato
Peter Webse
Company Secretary8.5yrsNessun datoNessun dato

0.9yrs

Durata media

Gestione esperta: Il team dirigenziale di RAC non è considerato esperto (durata media 0.9 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Peter Smith
Executive Chairman1.4yrsAU$327.72kNessun dato
Daniel Tillett
CEO, Managing Director & Directorless than a yearAU$1.12m10.13%
A$ 25.0m
Martin Tallman
Member of Scientific Advisory Board7.9yrsNessun datoNessun dato
Douglas Smith
Member of Scientific Advisory Boardno dataNessun datoNessun dato
Roland Walter
Member of Scientific Advisory Boardno dataNessun datoNessun dato
Borje Andersson
Chairman of Clinical Advisory Board4.9yrsAU$815.36kNessun dato
Jaap-Jan Boelens
Member of Clinical Advisory Board4.8yrsNessun datoNessun dato
Jianjun Chen
Member of Scientific Advisory Board3.6yrsNessun datoNessun dato
James Breitenbucher
Member of Scientific Advisory Board2.5yrsNessun datoNessun dato
Daniel Hoff
Clinical Advisory Boardless than a yearNessun datoNessun dato
Erin Howden
Member of Scientific Advisory Boardless than a yearNessun datoNessun dato
Serge Scrofani
Independent Non-Executive Directorless than a yearNessun datoNessun dato

2.0yrs

Durata media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di RAC non è considerato esperto (durata media del mandato 2 anni), il che suggerisce un nuovo consiglio.